CHICAGO and TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“ Wesana ” or the “ Company ”) ( CSE:WESA; OTCQB:WSNAF ), today announced the successful closing of the sale by Wesana Health Inc. (“WHI”), a subsidiary of the Company, of WHI’s right and interest in the SANA-013 intellectual property and development related assets (the “ Transaction ”) pursuant to the terms of the asset purchase agreement... Read More

CHICAGO and TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“ Wesana ” or the “ Company ”) ( CSE: WESA; OTCQB: WSNAF ), today announced that all matters put forward at the Company’s annual general and special meeting (the “ AGSM ”) of shareholders (“ Shareholders ”) held on June 9, 2023 were duly approved by the requisite majority of votes cast at the AGSM. AGSM Results A total of approximately eighty... Read More

CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, today announced that the Company has entered into a definitive asset purchase agreement dated March 20 2023 (the “Asset Purchase Agreement”) with Lucy Scientific Discovery Inc. (“Lucy”) (NASDAQ:LSDI) for the sale by Wesana Health Inc. (“WHI”), a... Read More

CHICAGO and TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. ( “ Wesana ” or the “ Company ” ) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company , today announced that Wesana Health Inc. (“ WHI ”), a subsidiary of the Company, has received an unsecured short-term loan in an aggregate principal amount of US$250,000 from an arm’s length lender (the “ Loan ”). The Loan will bear interest at a... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow, today announces that it successfully completed a transaction (the “Sale Transaction”) to sell the Management Services Organization (“MSO”) assets as part of the Company’s Care Delivery segment for a total consideration of USD$2,100,000. “The sale of the... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its second quarter 2022 financial results. H1 2022 Highlights Received positive feedback from pre-Investigational New Drug (“IND”) meeting with U.S. Food and Drug Administration (“FDA”) on... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be keynoting the upcoming Charles River Symposium, “ Re-imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies.” Charles River... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its first quarter 2022 financial results. Q1 2022 Highlights Delivered findings indicating psilocybin potentiates impact of anti-depressant Received positive feedback from pre-Investigational... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration (“FDA”), the Company is expanding its lead indication for SANA-013 to Major... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that following the successful completion of an initial tranche of its previously announced private placement (the “ Placement ”), the Company has determined to move forward with a strategic... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its fourth quarter and full-year 2021 financial results. Q4 2021 Highlights and Subsequent Events Exploring broadening SANA-013’s lead indication to treat Major Depressive Disorder (“MDD”)... Read More

Concurrently, the Company is launching a non-brokered private placement Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration (the... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be speaking at several investor and industry events over the coming weeks. Mr. Carcillo will be speaking at: Benzinga Psychedelics Capital Conference , Miami, April 19... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has announced data from an animal study, conducted by an independent global laboratory services provider in a validated model of depression. Results of the study showed that administration of imipramine given... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced that they have received a full written response from the Food and Drug Administration (FDA) regarding their pre-Investigational New Drug (IND) meeting for the novel therapy and proprietary protocol of... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced today that construction is underway for its third mental health clinic, expected to open in Spring 2022. This new 3000 square-foot facility will be located in the southwest part of Naperville, IL and will... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced the appointment of Meghna A. Gaeta as Chief Marketing Officer. In this role, she will lead Wesana’s business marketing strategy. “Meghna has a proven track record of brand innovation and development... Read More

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model A single high dose of psilocybin alone demonstrated rapid, significant, and short acting improvement in depressive behaviors up to 14 days following... Read More

Wesana granted pre-IND meeting with FDA, currently set for March 11, 2022 Wesana Clinics exhibited a record quarter of billings, new patient visits, telemedicine utilization, overall patient appointments, and ketamine administrations New flagship clinic set to open in late Q1 2022 showcasing the service evolution of Wesana Clinics Strategic restructuring program to realize $1.1M in general corporate overhead reduction and... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, is pleased to announce receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which validated and will expedite Wesana’s partnership talks with Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC). The parties will... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data-driven life sciences company, is pleased to announce that it has filed Patent Cooperation Treaty (“PCT”) patent applications towards securing the exclusive rights to protocols, delivery methods and compositions of matter which includes utilizing a high loading dose of psilocybin-assisted psychotherapy, coupled with non-hallucinogenic,... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data driven life sciences company, has announced its quarterly financial results for the three- and nine-month period ending September 30, 2021. Q3 2021 Highlights Ended the third quarter with US$11,266,187 in cash Completed the acquisition of PsyTech and related transactions, launching Care Delivery as a new business segment consisting of... Read More

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) , a data-driven life sciences company, announced today that the Company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception. Daniel Carcillo, CEO of Wesana Health commented, “This is a significant achievement for Wesana Clinics. There... Read More